Literature DB >> 35460406

Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice.

Eileen J Daley1, Sung-Hee Yoon1, Monica Reyes1, Michael Bruce1, Daniel J Brooks1, Mary Bouxsein1, John T Potts1, Henry M Kronenberg1, Marc N Wein1, Beate Lanske2, Harald Jüppner1, Thomas J Gardella1.   

Abstract

Rodent models are commonly used to evaluate parathyroid hormone (PTH) and PTH-related protein (PTHrP) ligands and analogues for their pharmacologic activities and potential therapeutic utility toward diseases of bone and mineral ion metabolism. Divergence, however, in the amino acid sequences of rodent and human PTH receptors (rat and mouse PTH1Rs are 91% identical to the human PTH1R) can lead to differences in receptor-binding and signaling potencies for such ligands when assessed on rodent vs human PTH1Rs, as shown by cell-based assays in vitro. This introduces an element of uncertainty in the accuracy of rodent models for performing such preclinical evaluations. To overcome this potential uncertainty, we used a homologous recombination-based knockin (KI) approach to generate a mouse (in-host strain C57Bl/6N) in which complementary DNA encoding the human PTH1R replaces a segment (exon 4) of the murine PTH1R gene so that the human and not the mouse PTH1R protein is expressed. Expression is directed by the endogenous mouse promoter and hence occurs in all biologically relevant cells and tissues and at appropriate levels. The resulting homozygous hPTH1R-KI (humanized) mice were healthy over at least 10 generations and showed functional responses to injected PTH analog peptides that are consistent with a fully functional human PTH1R in target bone and kidney cells. The initial evaluation of these mice and their potential utility for predicting behavior of PTH analogues in humans is reported here.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PTH1R; abaloparatide; class B GPCR; humanized mouse; parathyroid hormone receptor

Mesh:

Substances:

Year:  2022        PMID: 35460406      PMCID: PMC9167040          DOI: 10.1210/endocr/bqac054

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  43 in total

1.  Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.

Authors:  Masaru Shimizu; Eri Joyashiki; Hiroshi Noda; Tomoyuki Watanabe; Makoto Okazaki; Miho Nagayasu; Kenji Adachi; Tatsuya Tamura; John T Potts; Thomas J Gardella; Yoshiki Kawabe
Journal:  J Bone Miner Res       Date:  2016-05-23       Impact factor: 6.741

2.  Activation of the GLP-1 receptor by a non-peptidic agonist.

Authors:  Peishen Zhao; Yi-Lynn Liang; Matthew J Belousoff; Giuseppe Deganutti; Madeleine M Fletcher; Francis S Willard; Michael G Bell; Michael E Christe; Kyle W Sloop; Asuka Inoue; Tin T Truong; Lachlan Clydesdale; Sebastian G B Furness; Arthur Christopoulos; Ming-Wei Wang; Laurence J Miller; Christopher A Reynolds; Radostin Danev; Patrick M Sexton; Denise Wootten
Journal:  Nature       Date:  2020-01-08       Impact factor: 49.962

3.  Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH.

Authors:  Akira Maeda; Makoto Okazaki; David M Baron; Thomas Dean; Ashok Khatri; Mathew Mahon; Hiroko Segawa; Abdul B Abou-Samra; Harald Jüppner; Kenneth D Bloch; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

4.  Use of Backbone Modification To Enlarge the Spatiotemporal Diversity of Parathyroid Hormone Receptor-1 Signaling via Biased Agonism.

Authors:  Shi Liu; Frederic G Jean-Alphonse; Alex D White; Denise Wootten; Patrick M Sexton; Thomas J Gardella; Jean-Pierre Vilardaga; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2019-09-09       Impact factor: 15.419

Review 5.  Trends in GPCR drug discovery: new agents, targets and indications.

Authors:  Alexander S Hauser; Misty M Attwood; Mathias Rask-Andersen; Helgi B Schiöth; David E Gloriam
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

6.  Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.

Authors:  Carole Le Henaff; Florante Ricarte; Brandon Finnie; Zhiming He; Joshua Johnson; Johanna Warshaw; Victoria Kolupaeva; Nicola C Partridge
Journal:  J Bone Miner Res       Date:  2019-12-27       Impact factor: 6.741

7.  Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long-Acting PTH.

Authors:  Tadatoshi Sato; Shiv Verma; Ashok Khatri; Thomas Dean; Olga Goransson; Thomas J Gardella; Marc N Wein
Journal:  JBMR Plus       Date:  2021-05-06

Review 8.  Humanising the mouse genome piece by piece.

Authors:  Fei Zhu; Remya R Nair; Elizabeth M C Fisher; Thomas J Cunningham
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919

9.  A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.

Authors:  Lucy S Jun; Aaron D Showalter; Nosher Ali; Feihan Dai; Wenzhen Ma; Tamer Coskun; James V Ficorilli; Michael B Wheeler; M Dodson Michael; Kyle W Sloop
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

Review 10.  The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases.

Authors:  Fadil M Hannan; Enikö Kallay; Wenhan Chang; Maria Luisa Brandi; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.